CARsgen Therapeutics Holdings Limited (“CARsgen,” Stock Code: 2171) updated its existing share repurchase plan, increasing the authorized repurchase to a total of 25,461,295 shares on the open market within 50 Hong Kong trading days from November 13, 2025. Combined with the 3,310,500 shares already repurchased this year, these shares represent approximately 5% of the total issued shares under the 2025 Share Repurchase Mandate. The board believes the current share price does not fully reflect the company’s business prospects, and all repurchases will be funded through non-IPO raised funds such as business development income and interest income.

CARsgen also reported that YIJIE Biotech Holding Limited and parties acting in concert purchased 100,000 shares between November 6 and November 10, 2025. This raises YIJIE Concert Group’s total holdings to 218,048,730 shares, representing approximately 37.92% of the company’s issued shares (excluding treasury shares). According to the announcement, this development reflects the substantial shareholder’s confidence in CARsgen’s long-term investment value.

The company reminded investors that actual repurchases will depend on market conditions and be at the board’s discretion. There is no guarantee regarding timing, quantity, or price of any share repurchase, and shareholders are advised to exercise caution when dealing in the shares.